Effects of Combined Chemotherapy of SB225002 and Cisplatin on OSCC Cells In Vitro

doi:10.13701/j.cnki.kqyxyj.2016.02.007

Abstract

Abstract: Objective: To investigate the effects of SB225002 and cisplatin on oral squamous cell carcinoma (OSCC) cells, and meanwhile explore the possible mechanism. Methods: The OSCC cell proliferation, apoptosis and cell cycle were detected by MTT assay and flow cytometry after treated with SB225002 and cisplatin alone or in combination, and then correlated analysis was performed. Results: SB225002 could significantly inhibit the proliferation, promote apoptosis and induce G2/M arrest of OSCC cells in a concentration-dependent manner. Moreover, combined chemotherapy of SB225002 and cisplatin showed stronger effects, and the differences were statistically significant (P<0.05). Conclusion: There is synergistic effect between SB225002 and cisplatin on the anti-tumor activity in OSCC cells.

CLC Number:

R739.8

WANG Xian-ling, LIU Jian-wei, QIAN Yong.. Effects of Combined Chemotherapy of SB225002 and Cisplatin on OSCC Cells In Vitro[J]. Journal of Oral Science Research, 2016, 32(2): 134-138.

References

[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics[J]. 2002. CA Cancer J lin, 2005, 55∶74-108
[2] Rodriguez CP, Adelstein DJ. Survival trends in head and neck cancer: opportunities for improving outcomes[J]. Oncologist, 2010, 15∶921-3
[3] Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution[J]. Genome Biol, 2006, 7(12)∶243
[4] Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity[J]. J Immunol, 2000, 165(9)∶5269-77
[5] White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibitsinterleukin-8-induced neutrophil migration[J]. J Biol Chem, 1998, 273∶10095-98
[6] Sueoka H, Hirano T, Uda Y, et al. Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma[J]. Surgery, 2014, 155(4)∶640-9
[7] Goda AE, Koyama M, Sowa Y, et al. Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor[J]. Biochem Pharmacol, 2013, 85(12)∶1741-52
[8] Saintigny P, Massarelli E, Lin S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma[J]. Cancer Res, 2013, 73(2)∶571-82
[9] Machiels JP, Lambrecht M, Hanin FX, et al. Advances in the management of squamous cell carcinoma of the head and neck[J]. F1000Prime Rep, 2014, 6∶44
[10] Wolff KD, Follmann M, Nast A. The diagnosis and treatment of oral cavity cancer[J]. Dtsch Arztebl Int, 2012, 109(48)∶829-35
[11] Bredell M, Rordorf T, Studer G. Treatmentconceptsof oral cancer[J].SADJ, 2012, 67(10)∶574-6
[12] Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action[J]. Eur J Pharmacol, 2014, 740∶364-78
[13] Andreadis C, Vahtsevanos K, Sidiras T, et al. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer[J]. Oral Oncol, 2003, 39(4)∶380-5
[14] Ren W, Wang X, Gao L, et al. MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4[J]. Mol Cell Biochem, 2014, 390(1-2)∶253-62
[15] Shapiro LQ, Sherman EJ, Riaz N, et al. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)[J]. Oral Oncol, 2014, 50(10)∶947-55
[16] Huang CE, Yu CC, Hu FW, et al. Enhanced chemosensitivity by targeting Nanog in head and neck squamous cell carcinomas[J]. Int J Mol Sci, 2014, 15(9)∶14935-48
[17] Saintigny P, Massarelli E, Lin S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma[J]. Cancer Res, 2013, 73(2)∶571-82
[18] Lee YS, Choi I, Ning Y, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis[J]. Br J Cancer, 2012, 106(11)∶1833-41
[19] White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration[J]. J Biol Chem, 1998, 273(17)∶10095-8
[20] Catusse J, Liotard A, Loillier B, et al. Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogene alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2[J]. Biochem Pharmacol, 2003, 65(5):813-21
[21] Du M, Qiu Q, Gruslin A, et al. SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro[J]. PLoS One, 2013, 8(1)∶e54572
[22] Qian Y, Wang Y, Li DS, et al. The chemokine receptor-CXCR2 plays a critical role in the invasion and metastases of oral squamous cellcarcinoma in vitro and in vivo[J]. J Oral Pathol Med, 2014, 43(9)∶658-66
[23] 王雷,蔡研,孙宏晨.重组人乳铁蛋白对口腔癌细胞周期及周期因子表达影响的实验研究.口腔医学研究,2010,26(1)∶19-21
[24] Chang Q, Ornatsky OI, Koch CJ, et al. Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry[J]. Int J Cancer,2014,[Epub ahead of print]
[25] Liu FY, Wu YH, Zhou SJ, et al. Minocycline and cisplatin exert synergistic growth suppression on hepatocellular carcinoma by inducing S phase arrest and apoptosis[J]. Oncol Rep, 2014, 32(2)∶835-44